Truist Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.4M Sell
272,022
-3,844
-1% -$506K 0.04% 323
2026
Q1
$38.4M Sell
275,866
-34,074
-11% -$4.77M 0.05% 286
2025
Q4
$38M Sell
309,940
-397
-0.1% -$48.2K 0.05% 282
2025
Q3
$34.4M Sell
310,337
-42,786
-12% -$4.86M 0.05% 298
2025
Q2
$39.2M Sell
353,123
-7,052
-2% -$751K 0.06% 273
2025
Q1
$40.4M Sell
360,175
-9,560
-3% -$986K 0.06% 254
2024
Q4
$34.2M Sell
369,735
-17,375
-4% -$1.56M 0.05% 289
2024
Q3
$32.5M Sell
387,110
-19,791
-5% -$1.51M 0.05% 300
2024
Q2
$27.9M Sell
406,901
-39,572
-9% -$2.64M 0.04% 336
2024
Q1
$32.7M Sell
446,473
-47,044
-10% -$3.62M 0.05% 314
2023
Q4
$40M Sell
493,517
-79,928
-14% -$6.22M 0.06% 266
2023
Q3
$43M Buy
573,445
+7,890
+1% +$607K 0.07% 245
2023
Q2
$43.6M Sell
565,555
-95,273
-14% -$7.6M 0.07% 241
2023
Q1
$54.8M Sell
660,828
-162,731
-20% -$13.5M 0.09% 200
2022
Q4
$70.7M Sell
823,559
-98,617
-11% -$7.81M 0.12% 167
2022
Q3
$56.9M Buy
922,176
+145,515
+19% +$9.18M 0.11% 187
2022
Q2
$48M Buy
776,661
+78,158
+11% +$4.84M 0.09% 210
2022
Q1
$41.5M Sell
698,503
-25,743
-4% -$1.65M 0.07% 265
2021
Q4
$52.6M Buy
724,246
+3,034
+0.4% +$209K 0.08% 237
2021
Q3
$50.4M Sell
721,212
-355,713
-33% -$25M 0.08% 230
2021
Q2
$74.2M Sell
1,076,925
-22,152
-2% -$1.48M 0.12% 178
2021
Q1
$71M Buy
1,099,077
+62,826
+6% +$4.05M 0.12% 182
2020
Q4
$60.4M Sell
1,036,251
-53,068
-5% -$3.2M 0.12% 186
2020
Q3
$68.8M Buy
1,089,319
+136,708
+14% +$9.48M 0.15% 153
2020
Q2
$73.3M Sell
952,611
-273,784
-22% -$21M 0.16% 144
2020
Q1
$91.7M Sell
1,226,395
-262,916
-18% -$18.2M 0.24% 99
2019
Q4
$96.8M Buy
1,489,311
+1,357,504
+1,030% +$88.4M 0.2% 116
2019
Q3
$8.35M Buy
131,807
+8,817
+7% +$576K 0.14% 160
2019
Q2
$8.31M Sell
122,990
-3,164
-3% -$208K 0.14% 160
2019
Q1
$8.2M Buy
126,154
+736
+0.6% +$48.9K 0.15% 149
2018
Q4
$7.84M Sell
125,418
-82,147
-40% -$5.74M 0.16% 144
2018
Q3
$16M Sell
207,565
-15,241
-7% -$1.15M 0.29% 92
2018
Q2
$15.8M Sell
222,806
-5,021
-2% -$355K 0.3% 89
2018
Q1
$17.2M Sell
227,827
-7,833
-3% -$623K 0.33% 79
2017
Q4
$16.9M Sell
235,660
-19,479
-8% -$1.48M 0.32% 81
2017
Q3
$20.7M Sell
255,139
-26,891
-10% -$2.06M 0.4% 63
2017
Q2
$20M Sell
282,030
-4,099
-1% -$273K 0.4% 65
2017
Q1
$19.4M Buy
286,129
+3,232
+1% +$227K 0.39% 69
2016
Q4
$20.3M Buy
282,897
+1,107
+0.4% +$82.3K 0.41% 58
2016
Q3
$22.3M Buy
281,790
+1,026
+0.4% +$83.3K 0.46% 53
2016
Q2
$23.4M Buy
280,764
+139,781
+99% +$12.4M 0.49% 45
2016
Q1
$13M Buy
140,983
+20,122
+17% +$1.81M 0.34% 78
2015
Q4
$12.2M Sell
120,861
-12,639
-9% -$1.32M 0.32% 83
2015
Q3
$13.1M Sell
133,500
-14,912
-10% -$1.66M 0.34% 83
2015
Q2
$17.4M Sell
148,412
-12,962
-8% -$1.42M 0.47% 53
2015
Q1
$15.8M Sell
161,374
-15,678
-9% -$1.59M 0.45% 61
2014
Q4
$16.7M Sell
177,052
-12,073
-6% -$1.25M 0.49% 56
2014
Q3
$20.1M Sell
189,125
-13,789
-7% -$1.35M 0.61% 39
2014
Q2
$16.8M Sell
202,914
-7,522
-4% -$585K 0.5% 53
2014
Q1
$14.9M Buy
210,436
+2,006
+1% +$157K 0.47% 57
2013
Q4
$15.7M Sell
208,430
-438
-0.2% -$30.5K 0.5% 52
2013
Q3
$13.1M Buy
208,868
+6,445
+3% +$385K 0.47% 55
2013
Q2
$10.4M Buy
+202,423
New +$10.6M 0.39% 67

Other funds holding GILD

Truist Financial's GILD Position: Q2 2026 in Review

Truist Financial reduced its Gilead Sciences (GILD) stake by 1.4% in Q2 2026, selling an estimated $506K and leaving 272,022 shares worth $34.4M. The position accounts for 0.04% of the portfolio, ranked #323.

Truist Financial first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $96.8M in Q4 2019. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Truist Financial held 272,022 shares of Gilead Sciences worth $34.4M as of Q2 2026.
  • Truist Financial sold 3,844 Gilead Sciences shares in Q2 2026, an estimated $506K.
  • Gilead Sciences made up 0.04% of Truist Financial's portfolio in Q2 2026, its #323 holding.
  • Truist Financial first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Truist Financial's Gilead Sciences position peaked at $96.8M in Q4 2019.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.